Robles BioCeutics’ regenerative dermatology approach, using “injury mimetic” stimulated stem cell grafts, shows promise in treating sepsis, a leading cause of death.
SAN DIEGO, Dec. 31, 2024 — Robles BioCeutics reported new findings indicating that its “injury mimetic”-stimulated stem cell approach protects against sepsis in animal studies. Experiments showed that administering three-dimensional stem cell organoids lessened sepsis-related deaths in animal models, with complete protection seen when placental organoids were treated using the company’s method.
Sepsis, a life-threatening condition resulting from the body’s extreme immune response to infection, causes organ dysfunction and accounts for over 20 million deaths worldwide annually1. In the United States, it’s the third leading cause of death2.
“Adapting a skincare therapy into a potential sepsis treatment is truly remarkable,” stated Maxim Wheatley, Robles BioCeutics Advisory Board Member and JetPatient CEO. “This demonstrates innovative thinking and the power of leveraging top scientists to advance the boundaries of medicine.”
Robles BioCeutics previously patented its use of “injury mimetics” to boost the regenerative effects of its flagship product, Glowselle3. The company’s research is headed by Chief Scientific Officer Dr. Jorge Genovese, M.D., Ph.D., a prominent figure in stem cell and dermatological research4.
“At Robles BioCeutics, our focus is on science-driven progress,” said Maria Robles, the company’s President and CEO. “Collaboration with forward-thinking clinicians has opened up new avenues of research based on our core regenerative dermatology technology.”
The company is currently exploring collaborations for its sepsis treatment development.
About Robles BioCeutics
Robles BioCeutics is dedicated to providing science-based solutions for skin health and anti-aging. Founded by Maria Robles, the company leads innovation in skin care with its flagship product, Glowselle, which enhances natural beauty and vitality.
For updates, follow Robles BioCeutics on , , , and , or visit .
Media Contact:
Maria Robles
CEO
Robles BioCeutics
858-609-0948
1
2
3
4
SOURCE Robles BioCeutics